NASDAQ: SPNSSapiens International Corp N V Stock
$26.43+0.01 (+0.04%)
Updated Jan 23, 2025
SPNS Price
$26.43
Fair Value Price
$27.72
Market Cap
$1.48B
52 Week Low
$25.01
52 Week High
$41.22
P/E
20.65x
P/B
3.13x
P/S
3.86x
PEG
1.94x
Dividend Yield
2.16%
Revenue
$538.93M
Earnings
$71.29M
Gross Margin
43.4%
Operating Margin
15.76%
Profit Margin
13.2%
Debt to Equity
0.45
Operating Cash Flow
$79M
Beta
1.04
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SPNS Overview
Sapiens International Corporation N.V. provides software solutions for the insurance and financial services industries in North America, the European Union, the United Kingdom, Israel, and internationally. The company offers Sapiens CoreSuite and Sapiens IDITSuite for personal, commercial, and specialty lines; and Sapiens CoreSuite, Sapiens UnderwritingPro, Sapiens ApplicationPro, Sapiens IllustrationPro, and Sapiens ConsolidationMaster for life, pension, and annuities. It also provides Sapiens DigitalSuite for customers, agents, brokers, risk managers, customer groups and third-party service providers; Sapiens ReinsuranceMaster and Sapiens ReinsurancePro reinsurance solutions; and Sapiens Platform, Sapiens CoreSuite, Sapiens PolicyPro, and Sapiens ClaimsPro, as well as Sapiens PolicyGo, and Sapiens ClaimsGo for workers' compensation. In addition, the company offers financial and compliance solutions, which comprise Sapiens FinancialPro, Sapiens Financial GO, Sapiens StatementPro, Sapiens CheckPro, and Sapiens Reporting Tools; and Sapiens Decision, an enterprise-scale platform that enables institutions to centrally author, store, and manage various organizational business logics. Further, it provides tailor-made solutions based on its Sapiens eMerge platform; and program delivery, business, and managed services. The company markets and sells its products and services through direct and partner sales. Sapiens International Corporation N.V. was founded in 1982 and is headquartered in Holon, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SPNS's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
B
Value
C
Growth
C
Momentum
C
Sentiment
B
Safety
B
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: App
Industry Rating
B
SPNS
Ranked#40 of 208
Ranked#40 of 208
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.33 | A | |
| $3.95 | A | |
| $20.39 | A |
Be the first to know about important SPNS news, forecast changes, insider trades & much more!
SPNS News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SPNS scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SPNS ($26.43) is undervalued by 4.64% relative to our estimate of its Fair Value price of $27.72 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
SPNS ($26.43) is not significantly undervalued (4.64%) relative to our estimate of its Fair Value price of $27.72 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SPNS ($26.43) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more SPNS due diligence checks available for Premium users.
Valuation
SPNS fair value
Fair Value of SPNS stock based on Discounted Cash Flow (DCF)
Price
$26.43
Fair Value
$27.72
Undervalued by
4.64%
SPNS ($26.43) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SPNS ($26.43) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SPNS ($26.43) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SPNS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
20.65x
Industry
37.46x
Market
30.03x
SPNS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
SPNS is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
SPNS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.13x
Industry
7.96x
SPNS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SPNS price to earnings growth (PEG)
For valuing profitable companies with growth potential
SPNS is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
SPNS's financial health
Profit margin
Revenue
$137.0M
Net Income
$18.3M
Profit Margin
13.4%
SPNS's Earnings (EBIT) of $84.96M... subscribe to Premium to read more.
Interest Coverage Financials
SPNS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$683.3M
Liabilities
$212.0M
Debt to equity
0.45
SPNS's short-term assets ($321.39M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SPNS's short-term assets ($321.39M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SPNS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SPNS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$13.1M
Investing
$21.3M
Financing
-$14.2M
SPNS's operating cash flow ($78.76M)... subscribe to Premium to read more.
Debt Coverage Financials
SPNS vs App Stocks
Sapiens International N V Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.